COPD
Conditions
Interventions
After enrollment, they made 2 outpatient visits. At visit 1, patients'
baseline characteristics will be recorded and subjects will receive budesonide 200 microgram, 8 puffs daily for 28 days. At visit 2, 28 days after the enrollment, post-bronchodilator pulmonary functio
Sponsors
Department of Pulmonary Medicine, Kameda Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: COPD patients on treatment with LABA, LAMA, LAMA/LABA or none who were more than 40 years and met all of the following criteria will be recruited; current or ex-smokers of more than 10 pack-years, post-bronchodilator FEV1/forced vital capacity (FVC) ratio < 70%, FeNO > 35ppb.
Exclusion criteria
Exclusion criteria: We will exclude patients taking oral or inhaled corticosteroids within 1 month of trial entry. We will also exclud unstable COPD patients who have an exacerbation within 6 weeks of trial entry or have severe intercurrent diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is change of post-bronchodilator FEV1 by using high-dose ICS. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes are improvement of CAT score, %FEV1, %FVC. | — |
Countries
Japan
Contacts
Public ContactAkihiro Shiroshita
Kameda Medical Center pulmonology
Outcome results
None listed